Investors ready to resuscitate Johnson & Johnson’s ailing stock

NEW YORK (Reuters) – Johnson & Johnson (JNJ.N) shareholders have endured a painful year amid worries about prospects for its many businesses, but investors capitalizing on the stock’s relatively cheap valuation may be set to apply a Band-Aid to the declines.

FILE PHOTO: A Johnson & Johnson building is shown in Irvine, California, U.S., January 24, 2017. REUTERS/Mike Blake

Shares of J&J, the largest U.S. healthcare company by market value, had slumped 11.2 percent this year as of Friday’s close, although recent gains may indicate the start of a rebound. The stock’s year-to-date decline…

Read More Here

Be the first to comment on "Investors ready to resuscitate Johnson & Johnson’s ailing stock"

Leave a comment

Your email address will not be published.